

Company maintains its payout at 40% of consolidated net profit

Grifols holds its Annual General Meeting

- Grifols shareholders approved a total dividend payment of €59.18 million from 2009 profits, up 21.5% year-on-year
- The final agreement reached to buy Talecris Biotherapeutics was not contemplated in the Agenda.

Barcelona, 21 June 2010.- Grifols, a Spanish holding company specializing in the pharmaceutical-hospital industry and one of the world's leading producers of plasma derivatives, held its Annual General Meeting today at first call. 918 shareholders, holding 206,974,392 voting shares, equivalent to 97.1% of the company's share capital were present or duly represented.

Votes representing 95.5% of capital were delegated in the Board of Directors, underscoring shareholder support both for the Group's management, its execution of the business plan and the future strategy being implemented which includes, among others, the possible acquisition of Talecris Biotherapeutics, after the final agreement reached last June 7 by the Boards of Directors of both companies. This notwithstanding, the closing of this transaction is subject to the usual terms and conditions customarily applied to this type of transactions, including the authorisations of regulatory and competition authorities, as well as the respective approvals by the shareholders of each company. The approval is not included in the agenda of the Annual General Meeting of Grifols, and shall therefore be the object of an Extraordinary Meeting to be convened in due course.

To date, the growth strategy applied by Grifols during the last few years has been backed by the unanimous endorsement of shareholders and investors in the group. Grifols has thus been able to position itself as a global leader in the plasma derivatives sector, increase its presence in the United States and foster the group's international expansion, with presence in 90 countries and 22 subsidiaries worldwide. This strategy has also led to the implementation of a vertically integrated business model, in which obtaining plasma as a raw material, fractionation and purification production processes and marketing of plasma derivatives are totally controlled by Grifols, following the strictest quality and safety standards.

During his speech, the company's President, Victor Grifols, highlighted the outstanding sustained growth posted by the group also in 2009: *"In a challenging year characterized by the credit crunch, we have been one of the few Spanish companies backed by the unanimous endorsement of banks and investors. We have raised considerable additional financial resources, which means not only that we will grow, but also that markets are*

convinced that we will. This would however not have been possible without consistently obtaining sound results to endorse it”.

The president of the group reminded that “the revenues of all our divisions have performed positively in all quarters considered individually. Sales of plasma derivatives included in the Bioscience division increased by 12.5% to EUR 695.0 million, those of Diagnostic grew by 20.2% and reached EUR 103.1 million, while revenues of Hospital went up 4.7% and stood at EUR 86.3 million. In total, we closed 2009 with an increase in turnover of 12.1% up to EUR 913.2 million, and of 21.6% in net profit, which reached EUR 148.0 million, thus achieving the twofold objective of improving margins and reducing costs, criteria that all business areas should comply with. In addition, our EBITDA margin remains at 29.1% on sales, posting a growth of 12.6% as compared with the prior year, reaching EUR 266.1 million”

Finally, during his speech, he also stressed that “the achievements of 2009 are the result of a sound ethical, practical and legal philosophy that guarantees growth and enables the search for opportunities”, noting that “cost reduction has not affected our investment policy nor R+D, key aspects to ensure our growth”.

However, completing the purchase of Talecris would consolidate Grifols as the third producer of plasma derivatives worldwide, balancing the sector of biological plasma-derivatives products for the benefit of patients and generating operating synergies estimated at around USD 230 million p.a., in addition to other synergies related to the rationalization of capital investments (CAPEX), working capital, etc. In addition, we expect that, following the transaction, profits of Grifols will increase from year one, with more significant increase taking place from the second year on. We estimate that annual pro-forma income following the acquisition will rise to USD 2,800 million.

Grifols expects to gradually reduce its net financial debt/EBITDA ratio, achieving levels similar to the current ones by the end of 2014, as a consequence of significant increases of short-term cash flows and of synergies expected. While we expect the net financial debt over EBITDA ratio to stand, immediately following the transaction, approximately at 5x, this ratio should gradually reduce to approximately 3x EBITDA by the end of 2012 and below 2x towards the end of 2014, even while maintaining the main investment programmes.

Grifols to pay its shareholders 40% of net consolidated profit of the group

Among the items on the agenda, in addition to reviewing and approving the company's individual and consolidated 2009 financial statements and the respective management reports, was the approval of an ordinary before-tax per share dividend of 0.281 from 2009 profits. In all, Grifols will earmark €59.18 million to dividends, which translates into a payout of 40% of profits. The company is thereby maintaining its shareholder remuneration policy through dividends, as announced.

As regards to the payment of the dividend, EUR 31.96 (gross EUR 0.153 per share) were distributed among the shareholders on December 18 2009, as an interim dividend on account of the profits of the year, since the Annual General Meeting for 2008 resolved to pay dividends against the profits of the year in two payments. Therefore, having made a first payment in advance, the amount outstanding to be distributed by way of dividend is EUR 27.23 million (gross EUR 0.128 per share). This amount will be paid from July 1, 2010, through Iberclear and its participating entities, BBVA acting as payment agent.

Lastly, at the proposal of the Board of Directors, the company's shareholders approved the reappointment of Mr. Tomás Dagá as external director and of Mr. Edgar Jannotta and Ms. Anna Veiga Lluçh as independent directors of the company for a five year term as stipulated by the by-laws

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Stock Exchange ("Mercado Continuo") and is part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, thanks to recent investments. In terms of raw materials, Grifols has ensured its plasma supply with 80 plasmapheresis centers in the United States and in terms of fractionation, its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the growing market demand. Nevertheless, the company is preparing for sustained growth in the following 8-10 years and has launched an ambitious investment plan.

DISCLAIMER

The proposed merger transaction involving Grifols and Talecris will be submitted to the stockholders of Talecris for their consideration. In connection with the proposed merger, Grifols will file with the SEC a registration statement on Form F-4 that will include a joint proxy statement/prospectus of Grifols and Talecris. Talecris will mail the joint proxy statement/prospectus to its stockholders. Talecris urges investors and security holders to read the joint proxy statement/prospectus regarding the proposed transaction when it becomes available because it will contain important information regarding Grifols, Talecris and the proposed business combination. You may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about Talecris, without charge, at the SEC's website (<http://www.sec.gov>). You may also obtain these documents, without charge, from Talecris's website, <http://www.talecris.com>, under the tab "Investor Relations" and then under the heading "Financial Information and SEC Filings". Grifols will also file certain documents with the Spanish Comision Nacional del Mercado de Valores (the "CNMV") in connection with its shareholders' meeting to be held in connection with the proposed business combination, which will be available on the CNMV's website at www.cnmv.es.

Grifols, Talecris and their respective directors, executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies from the respective stockholders of Grifols and Talecris in favor of the merger. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the respective stockholders of Grifols and Talecris in connection with the proposed merger will be set forth in the joint proxy statement/prospectus when it is filed with the SEC. You can find information about Talecris's executive officers and directors in its Form S-1/A filed with the SEC on September 11, 2009. You can obtain free copies of this document from Talecris's website.

This press release is not an offer to sell or the solicitation of an offer to buy common stock, which is made only pursuant to a prospectus forming a part of a registration statement, nor

GRIFOLS

shall there be any sale of common stock in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of any such state. The Grifols shares have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law (Law 24/1988, of July 28, as amended and restated from time to time), Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.